Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery.
adjuvants
biomaterials
cancer immunotherapy
immunomaterials
peptide hydrogels
supramolecular assembly
vaccines
Journal
Advanced healthcare materials
ISSN: 2192-2659
Titre abrégé: Adv Healthc Mater
Pays: Germany
ID NLM: 101581613
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
15
05
2023
received:
06
04
2023
pmc-release:
01
10
2024
medline:
30
10
2023
pubmed:
31
5
2023
entrez:
31
5
2023
Statut:
ppublish
Résumé
Peptide-based hydrogel biomaterials have emerged as an excellent strategy for immune system modulation. Peptide-based hydrogels are supramolecular materials that self-assemble into various nanostructures through various interactive forces (i.e., hydrogen bonding and hydrophobic interactions) and respond to microenvironmental stimuli (i.e., pH, temperature). While they have been reported in numerous biomedical applications, they have recently been deemed promising candidates to improve the efficacy of cancer immunotherapies and treatments. Immunotherapies seek to harness the body's immune system to preemptively protect against and treat various diseases, such as cancer. However, their low efficacy rates result in limited patient responses to treatment. Here, the immunomaterial's potential to improve these efficacy rates by either functioning as immune stimulators through direct immune system interactions and/or delivering a range of immune agents is highlighted. The chemical and physical properties of these peptide-based materials that lead to immuno modulation and how one may design a system to achieve desired immune responses in a controllable manner are discussed. Works in the literature that reports peptide hydrogels as adjuvant systems and for the delivery of immunotherapies are highlighted. Finally, the future trends and possible developments based on peptide hydrogels for cancer immunotherapy applications are discussed.
Identifiants
pubmed: 37256647
doi: 10.1002/adhm.202301096
pmc: PMC10615713
mid: NIHMS1917826
doi:
Substances chimiques
Hydrogels
0
Peptides
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2301096Subventions
Organisme : NCI NIH HHS
ID : R01 CA257558
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK130566
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL140951
Pays : United States
Informations de copyright
© 2023 Wiley-VCH GmbH.
Références
Nat Nanotechnol. 2021 May;16(5):538-548
pubmed: 33526838
Nanoscale. 2017 Sep 28;9(37):14058-14064
pubmed: 28895610
ACS Appl Mater Interfaces. 2018 Dec 5;10(48):41046-41055
pubmed: 30475573
J Control Release. 2010 Mar 19;142(3):384-91
pubmed: 19951731
Front Immunol. 2013 Dec 11;4:438
pubmed: 24376443
Adv Mater. 2012 Jul 24;24(28):3845-9
pubmed: 22550019
Nat Commun. 2018 Apr 18;9(1):1532
pubmed: 29670088
Curr Opin Immunol. 2015 Aug;35:73-9
pubmed: 26163376
Adv Healthc Mater. 2017 Nov;6(21):
pubmed: 28782184
Clin Hemorheol Microcirc. 2008;39(1-4):205-12
pubmed: 18503127
Molecules. 2022 Jan 10;27(2):
pubmed: 35056735
Chem Commun (Camb). 2019 Oct 10;55(82):12388-12391
pubmed: 31559988
ACS Biomater Sci Eng. 2021 May 10;7(5):1876-1888
pubmed: 33775089
Front Immunol. 2018 Nov 28;9:2798
pubmed: 30546367
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
Nano Lett. 2017 Dec 13;17(12):7447-7454
pubmed: 29172544
Science. 2010 May 21;328(5981):1031-5
pubmed: 20378772
Vaccine. 2014 Aug 20;32(37):4743-50
pubmed: 24968155
J Control Release. 2018 Jul 28;282:120-130
pubmed: 29673645
Biomater Sci. 2021 Dec 7;9(24):8090-8110
pubmed: 34762077
ACS Biomater Sci Eng. 2018 Jun 11;4(6):2046-2052
pubmed: 33445275
Langmuir. 2009 Aug 18;25(16):9447-53
pubmed: 19537819
Bioact Mater. 2021 Apr 16;6(11):3924-3934
pubmed: 33997486
RSC Adv. 2020 Apr 6;10(23):13900-13906
pubmed: 35493019
Nat Rev Clin Oncol. 2022 Apr;19(4):254-267
pubmed: 35082367
Biomaterials. 2017 Sep;140:16-25
pubmed: 28623721
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
MRS Bull. 2014 Jan 1;39(1):25-34
pubmed: 26997752
Biomaterials. 2021 Jan;265:120401
pubmed: 33002786
Trends Cancer. 2018 Jun;4(6):418-428
pubmed: 29860986
Bioact Mater. 2022 Jan 03;16:359-371
pubmed: 35386314
Biomacromolecules. 2018 Mar 12;19(3):782-792
pubmed: 29384665
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Soft Matter. 2019 Feb 20;15(8):1704-1715
pubmed: 30724947
Biomater Sci. 2022 Jun 14;10(12):3092-3098
pubmed: 35522938
ACS Biomater Sci Eng. 2019 Sep 9;5(9):4657-4670
pubmed: 33448838
Bioeng Transl Med. 2017 May 16;2(2):139-155
pubmed: 28932817
Pharmaceutics. 2022 Dec 01;14(12):
pubmed: 36559179
Adv Sci (Weinh). 2020 Apr 28;7(11):1903392
pubmed: 32537404
J Immunother Cancer. 2021 May;9(5):
pubmed: 34016721
Adv Drug Deliv Rev. 2017 May 15;114:184-192
pubmed: 28712923
Nano Lett. 2019 Mar 13;19(3):1719-1727
pubmed: 30724087
Cells. 2021 Sep 10;10(9):
pubmed: 34572028
Annu Rev Pathol. 2021 Jan 24;16:167-198
pubmed: 33264572
Cell Mol Immunol. 2017 Aug;14(8):662-674
pubmed: 28626234
Nat Rev Cancer. 2021 May;21(5):298-312
pubmed: 33750922
Biomacromolecules. 2021 Sep 13;22(9):3992-4003
pubmed: 34464095
Adv Healthc Mater. 2013 Oct;2(10):1388-400
pubmed: 23554376
Angew Chem Int Ed Engl. 2017 Oct 16;56(43):13288-13292
pubmed: 28837256
Int J Mol Sci. 2022 Mar 03;23(5):
pubmed: 35269922
Sci Adv. 2022 Jul 22;8(29):eabm7833
pubmed: 35857833
Cancer J. 2011 Sep-Oct;17(5):359-71
pubmed: 21952287
Biomaterials. 2021 Jan;268:120549
pubmed: 33278685
Nat Rev Clin Oncol. 2018 Jan;15(1):11-12
pubmed: 28975930
ACS Nano. 2018 Oct 23;12(10):9693-9701
pubmed: 30183253
Biomaterials. 2021 May;272:120767
pubmed: 33813259
Gels. 2022 Nov 01;8(11):
pubmed: 36354614
ACS Appl Mater Interfaces. 2014 Apr 23;6(8):5558-65
pubmed: 24660962
J Control Release. 2017 Dec 28;268:176-183
pubmed: 29056443
Curr Opin Struct Biol. 2020 Aug;63:97-105
pubmed: 32512499
Adv Healthc Mater. 2013 Jan;2(1):72-94
pubmed: 23225517
Nat Mater. 2015 Jun;14(6):643-51
pubmed: 25985456
Sci Adv. 2022 Jan 21;8(3):eabj0305
pubmed: 35044831
Int J Mol Sci. 2011;12(9):5736-46
pubmed: 22016623
Adv Drug Deliv Rev. 2017 Feb;110-111:65-79
pubmed: 27535485
Cancer Immunol Res. 2017 Mar;5(3):222-233
pubmed: 28143806
Biomacromolecules. 2014 Sep 8;15(9):3246-52
pubmed: 25102223
Sci Adv. 2020 Aug 07;6(32):eaba0995
pubmed: 32821819
Acta Biomater. 2019 Sep 1;95:3-31
pubmed: 30481608
Polymers (Basel). 2021 Jul 03;13(13):
pubmed: 34279352
ACS Biomater Sci Eng. 2020 Sep 14;6(9):4774-4798
pubmed: 33455212
BMC Med. 2016 May 05;14:73
pubmed: 27151159
Trends Biotechnol. 2016 Jun;34(6):470-482
pubmed: 27138899
Adv Mater. 2017 Feb;29(5):
pubmed: 27859662
Bioact Mater. 2017 Sep 06;3(1):118-128
pubmed: 29744449
J Control Release. 2017 Jun 10;255:81-93
pubmed: 28408199
J Mater Chem B. 2022 Sep 28;10(37):7183-7193
pubmed: 35348177
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Acta Biomater. 2018 Mar 15;69:107-119
pubmed: 29248638
Cancer Gene Ther. 2022 Jan;29(1):10-21
pubmed: 33603130
Semin Oncol. 2012 Jun;39(3):276-86
pubmed: 22595050
Anal Chem. 2021 May 18;93(19):7355-7361
pubmed: 33957042
Pharmacol Res. 2022 Jan;175:106036
pubmed: 34920118
J Am Chem Soc. 2022 Sep 14;144(36):16512-16523
pubmed: 36049084
Adv Healthc Mater. 2014 Nov;3(11):1898-908
pubmed: 24923735
Biomacromolecules. 2017 Nov 13;18(11):3563-3571
pubmed: 28828862
Biomacromolecules. 2020 Apr 13;21(4):1613-1624
pubmed: 32091881
J Clin Neurosci. 2018 Oct;56:163-168
pubmed: 30041899
Biomaterials. 2020 Feb;231:119667
pubmed: 31855625
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):622-7
pubmed: 20080728
Biotechnol Adv. 2017 Sep;35(5):575-596
pubmed: 28522213
Nat Biotechnol. 2016 Mar;34(3):345-52
pubmed: 26807527
Crit Rev Immunol. 2012;32(6):463-88
pubmed: 23428224
J Am Chem Soc. 2013 Jul 3;135(26):9907-14
pubmed: 23742714
Biomacromolecules. 2017 Nov 13;18(11):3514-3523
pubmed: 28721731
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
Adv Mater. 2018 Jul;30(28):e1801527
pubmed: 29786888
Macromol Biosci. 2022 Jun;22(6):e2200043
pubmed: 35332672
J Hematol Oncol. 2019 Nov 28;12(1):126
pubmed: 31779642
ACS Appl Mater Interfaces. 2018 Apr 18;10(15):12474-12484
pubmed: 29584396
Angew Chem Int Ed Engl. 2011 Feb 11;50(7):1635-9
pubmed: 21308921
Adv Healthc Mater. 2018 Jun;7(12):e1701324
pubmed: 29577678
Biomater Sci. 2020 Jun 21;8(12):3522-3535
pubmed: 32452474
Biomacromolecules. 2017 Nov 13;18(11):3621-3629
pubmed: 28953367
Langmuir. 2017 Apr 4;33(13):3234-3240
pubmed: 28282150
Macromol Biosci. 2021 Jun;21(6):e2100049
pubmed: 33871152
Curr Opin Immunol. 2014 Apr;27:46-52
pubmed: 24534448
Nat Commun. 2019 Nov 27;10(1):5408
pubmed: 31776331
Biomacromolecules. 2017 Nov 13;18(11):3541-3550
pubmed: 28825801
Nat Rev Cancer. 2004 Jan;4(1):11-22
pubmed: 14708024
Nat Commun. 2022 Jun 28;13(1):3703
pubmed: 35764641
ACS Nano. 2013 May 28;7(5):3926-38
pubmed: 23631767
Materials (Basel). 2022 Aug 25;15(17):
pubmed: 36079250
Chemistry. 2018 Sep 25;24(54):14316-14328
pubmed: 29667727
Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):49
pubmed: 30263032
Biomater Sci. 2018 May 29;6(6):1480-1491
pubmed: 29623975
Biomaterials. 2020 Oct;256:120216
pubmed: 32736171
Adv Drug Deliv Rev. 2022 Aug;187:114401
pubmed: 35750115
Cancers (Basel). 2011 Oct 13;3(4):3856-93
pubmed: 24213115
Biomaterials. 2017 Jul;134:117-127
pubmed: 28458029
Mol Pharm. 2019 Jun 3;16(6):2326-2341
pubmed: 31026168
Nat Rev Cancer. 2021 Aug;21(8):481-499
pubmed: 34083781
J Control Release. 2021 Feb 10;330:1208-1219
pubmed: 33229053
Indian J Med Res. 2013 Nov;138(5):779-95
pubmed: 24434331
J Hematol Oncol. 2022 Mar 18;15(1):28
pubmed: 35303904
Front Immunol. 2021 Jun 30;12:696791
pubmed: 34276688
Sci Adv. 2020 Apr 29;6(18):eaaz8985
pubmed: 32490201
Nano Lett. 2018 Jul 11;18(7):4377-4385
pubmed: 29932335
Adv Sci (Weinh). 2020 Mar 20;7(9):1903718
pubmed: 32382486
ACS Omega. 2023 Jan 30;8(5):4677-4686
pubmed: 36777619
Stem Cell Rev Rep. 2019 Oct;15(5):619-636
pubmed: 31161552
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17867-72
pubmed: 15601762
Biomaterials. 2017 Dec;149:1-11
pubmed: 28982051
J Clin Invest. 2017 Jun 1;127(6):2176-2191
pubmed: 28436934
ACS Nano. 2018 Apr 24;12(4):3295-3310
pubmed: 29558107
Curr Pharm Biotechnol. 2018;19(1):5-18
pubmed: 29667553
ACS Appl Mater Interfaces. 2016 Sep 28;8(38):25036-42
pubmed: 27598654
Adv Healthc Mater. 2016 Oct;5(20):2575-2594
pubmed: 27593734
Biomaterials. 2010 May;31(13):3479-91
pubmed: 20138663
Nat Rev Drug Discov. 2021 Jul;20(7):531-550
pubmed: 33972771
Adv Mater. 2020 Oct;32(39):e2003310
pubmed: 32820582
Sci Adv. 2022 Apr 8;8(14):eabn8264
pubmed: 35394838
Vaccines (Basel). 2022 Dec 27;11(1):
pubmed: 36679904
Nat Rev Cancer. 2018 Aug;18(8):485-499
pubmed: 29703913
Adv Ther (Weinh). 2021 Aug;4(8):
pubmed: 34734110
J Hematol Oncol. 2018 Feb 13;11(1):22
pubmed: 29433552
Biomaterials. 2018 Mar;159:119-129
pubmed: 29324304
Vaccines (Basel). 2022 Jan 17;10(1):
pubmed: 35062791
Chem Rev. 2020 Mar 25;120(6):3210-3229
pubmed: 31804810
Biomaterials. 2021 Jun;273:120825
pubmed: 33901731
Front Chem. 2020 Jul 21;8:500
pubmed: 32850613
Virchows Arch. 2019 Apr;474(4):449-461
pubmed: 30470934
Adv Drug Deliv Rev. 2021 Jul;174:482-503
pubmed: 34015417
ACS Appl Mater Interfaces. 2018 Jun 20;10(24):20256-20270
pubmed: 29808986
ACS Nano. 2010 Jun 22;4(6):3073-86
pubmed: 20507158
Biomater Sci. 2020 Oct 21;8(20):5601-5614
pubmed: 32832942
Adv Mater. 2014 Oct;26(38):6530-41
pubmed: 25155610
Theranostics. 2019 May 24;9(11):3388-3397
pubmed: 31244959
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7919-E7928
pubmed: 28874575
Biomater Sci. 2022 Oct 25;10(21):6217-6229
pubmed: 36102692
Biomaterials. 2013 Nov;34(34):8776-85
pubmed: 23953841
Theranostics. 2019 Apr 12;9(8):2299-2314
pubmed: 31149045
Front Immunol. 2021 Mar 09;12:636568
pubmed: 33767702
J Interferon Cytokine Res. 2019 Jan;39(1):6-21
pubmed: 29889594
Bioact Mater. 2022 May 13;19:678-689
pubmed: 35600970